Avenue Therapeutics, Inc.

AI-generated fair value estimate for this company.

Method: Net asset value approach: total assets of $2.5M less total liabilities of $1.3M imply stockholders' equity of approximately $1.2M as of March 31 2026, divided by 3,294,967 common shares outstanding, with no positive value assigned to the early-stage pipeline.

Reasoning: Avenue Therapeutics carries an explicit going-concern qualification, an accumulated deficit of $106.2M, essentially no revenue, and a minimal balance sheet, so a net-asset/liquidation-value approach is the only defensible method rather than a DCF.